272 related articles for article (PubMed ID: 31195184)
1. Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Johannessen Landmark C; Fløgstad I; Baftiu A; Syvertsen M; Enger U; Koht J; Johannessen SI
Epilepsy Res; 2019 Sep; 155():106148. PubMed ID: 31195184
[TBL] [Abstract][Full Text] [Related]
2. Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Johannessen Landmark C; Fløgstad I; Syvertsen M; Baftiu A; Enger U; Koht J; Johannessen SI
Epilepsy Behav; 2019 Sep; 98(Pt A):110-116. PubMed ID: 31330379
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.
Serafini A; Gerard E; Genton P; Crespel A; Gelisse P
CNS Drugs; 2019 Mar; 33(3):195-208. PubMed ID: 30747367
[TBL] [Abstract][Full Text] [Related]
4. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center.
Cação G; Parra J; Mannan S; Sisodiya SM; Sander JW
Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081
[TBL] [Abstract][Full Text] [Related]
5. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy.
Prasad A; Kuzniecky RI; Knowlton RC; Welty TE; Martin RC; Mendez M; Faught RE
Arch Neurol; 2003 Aug; 60(8):1100-5. PubMed ID: 12925366
[TBL] [Abstract][Full Text] [Related]
6. Treatment of juvenile myoclonic epilepsy.
Auvin S
CNS Neurosci Ther; 2008; 14(3):227-33. PubMed ID: 18684236
[TBL] [Abstract][Full Text] [Related]
7. [Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate].
Crespel A; Velizarova R; Genton P; Gélisse P
Therapie; 2009; 64(5):321-3. PubMed ID: 19863907
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Chowdhury A; Brodie MJ
Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
[TBL] [Abstract][Full Text] [Related]
9. Antiepileptic drug withdrawal in juvenile myoclonic epilepsy.
Syvertsen M; Fløgstad I; Enger U; Landmark CJ; Koht J
Acta Neurol Scand; 2019 Feb; 139(2):192-198. PubMed ID: 30378684
[TBL] [Abstract][Full Text] [Related]
10. Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study.
Milano C; Turco F; Pizzanelli C; Bonanni E; Siciliano G; Fornai F; Giorgi FS
Epilepsy Behav; 2021 Feb; 115():107706. PubMed ID: 33423017
[TBL] [Abstract][Full Text] [Related]
11. Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020.
Kılıç B; Serdaroğlu E; Polat BG; İnce T; Esenülkü G; Topçu Y; Serdaroğlu A; Haspolat Ş; Tekgül H; Okuyaz Ç; Cansu A; Aydın K
Seizure; 2022 Jul; 99():48-53. PubMed ID: 35594744
[TBL] [Abstract][Full Text] [Related]
12. Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME).
Asadi-Pooya AA; Hashemzehi Z; Emami M
Seizure; 2014 Nov; 23(10):889-91. PubMed ID: 25189101
[TBL] [Abstract][Full Text] [Related]
13. High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: Going from low to high.
Hernández-Vanegas LE; Jara-Prado A; Ochoa A; Rodríguez Y Rodríguez N; Durón RM; Crail-Meléndez D; Alonso ME; Delgado-Escueta AV; Martínez-Juárez IE
Epilepsy Behav; 2016 Aug; 61():34-40. PubMed ID: 27300146
[TBL] [Abstract][Full Text] [Related]
14. Levetiracetam and Valproate Retention Rate in Juvenile Myoclonic Epilepsy.
Sala-Padró J; Toledo M; Santamarina E; González-Cuevas M; Raspall-Chaure M; Sueiras-Gil M; Quintana M; Salas-Puig X
Clin Neuropharmacol; 2016; 39(6):299-301. PubMed ID: 27438183
[TBL] [Abstract][Full Text] [Related]
15. Electroclinical aspects and therapy of Han patients with juvenile myoclonic epilepsy in northern China.
Wang L; Jiang Z; Chen BB; Wang CT; Wang JX; Bai J; Wang B; Jin L; Zhang WJ; Deng YC; Zhao G; Dang JX; Wang D; Jia SS; Wang TC; Jia FY; Zhang L; Liu YH
Epilepsy Behav; 2016 Sep; 62():204-8. PubMed ID: 27494356
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome.
Johannessen Landmark C; Heger K; Lund C; Burns ML; Bjørnvold M; Sætre E; Johannessen SI
Ther Drug Monit; 2020 Oct; 42(5):744-753. PubMed ID: 32558674
[TBL] [Abstract][Full Text] [Related]
17. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Montouris G; Abou-Khalil B
Epilepsia; 2009 Sep; 50 Suppl 8():16-20. PubMed ID: 19702728
[TBL] [Abstract][Full Text] [Related]
18. Relapse after treatment withdrawal of antiepileptic drugs for Juvenile Absence Epilepsy and Juvenile Myoclonic Epilepsy.
Healy L; Moran M; Singhal S; O'Donoghue MF; Alzoubidi R; Whitehouse WP
Seizure; 2018 Jul; 59():116-122. PubMed ID: 29807291
[TBL] [Abstract][Full Text] [Related]
19. Seizure outcome in 175 patients with juvenile myoclonic epilepsy--a long-term observational study.
Höfler J; Unterberger I; Dobesberger J; Kuchukhidze G; Walser G; Trinka E
Epilepsy Res; 2014 Dec; 108(10):1817-24. PubMed ID: 25443450
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy.
Ascoli M; Mastroianni G; Gasparini S; Striano P; Cianci V; Neri S; Bova V; Mammì A; Gambardella A; Labate A; Aguglia U; Ferlazzo E
Expert Rev Neurother; 2021 Nov; 21(11):1265-1273. PubMed ID: 33993822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
